{"entity":{"id":"nec-bio","kind":"company","name":"NEC Bio","aka":["NEC Bio B.V.","NEC OncoImmunity","NEC Bio Therapeutics"],"tldr":"NEC Bio is a Netherlands-based biotechnology company that leads 2 cancer trials in OnCo, testing the personalised neoantigen vaccine NECVAX-NEO1 in triple-negative breast cancer and advanced solid tumours.","summary":"NEC Bio is the holding company set up by NEC Corporation in 2023 to unify its AI-driven drug discovery and development activities; it manages NEC OncoImmunity in Oslo and NEC Bio Therapeutics in Mannheim. The group applies its immune-recognition AI platform to personalised neoantigen cancer vaccines, including NECVAX-NEO1. It is a wholly owned subsidiary of NEC Corporation. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06631079 (phase 1/2, Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy...) and NCT06631092 (phase 1/2, Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-nega...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.nec-bio.com/"},{"label":"ClinicalTrials.gov: trials led by NEC Bio","url":"https://clinicaltrials.gov/search?lead=NEC%20Bio%20B.V"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06631079","nct06631092"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Schiphol","country":"NL","companyType":"biotech","website":"https://www.nec-bio.com/","founded":2023,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/nec-bio/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"trial":[{"id":"nct06631079","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","route":"/trials/nct06631079/"},{"id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","route":"/trials/nct06631092/"}]}}